Avolition as the core negative symptom in schizophrenia: relevance to pharmacological treatment development

Gregory P. Strauss, Lisa A. Bartolomeo, Philip D. Harvey

Research output: Contribution to journalReview articlepeer-review

Abstract

Negative symptoms have long been considered a core component of schizophrenia. Modern conceptualizations of the structure of negative symptoms posit that there are at least two broad dimensions (motivation and pleasure and diminished expression) or perhaps five separable domains (avolition, anhedonia, asociality, blunted affect, alogia). The current review synthesizes a body of emerging research indicating that avolition may have a special place among these dimensions, as it is generally associated with poorer outcomes and may have distinct neurobiological mechanisms. Network analytic findings also indicate that avolition is highly central and interconnected with the other negative symptom domains in schizophrenia, and successfully remediating avolition results in global improvement in the entire constellation of negative symptoms. Avolition may therefore reflect the most critical treatment target within the negative symptom construct. Implications for targeted treatment development and clinical trial design are discussed.

Original languageEnglish (US)
Article number16
Journalnpj Schizophrenia
Volume7
Issue number1
DOIs
StatePublished - Dec 2021

ASJC Scopus subject areas

  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Avolition as the core negative symptom in schizophrenia: relevance to pharmacological treatment development'. Together they form a unique fingerprint.

Cite this